Lupin Acquires Biocom in Russia
Pharma Major Lupin Limited hasannounced the acquisition of 100% equity stake in ZAO “Biocom” in Russia subject to certain closing conditions. The acquisition marks Lupin’s foray into the Russian pharmaceutical market which recorded RUB 765 billion in sales, placing it as one of the Top 10 pharmaceutical markets in the world in 2014 (IMS Health). For over a decade, Russian pharmaceutical market recorded double digit growth and expected to continue with this trend, projecting Russia to be one of the Top 8 pharmaceutical markets in the world by 2018 (IMS Health).
Established in 1991, Biocom is a fast growing generic pharmaceutical company with a major focus on therapies such as cardiovascular, central nervous system and antimicrobials for systemic use and also does contract manufacturing and secondary packaging. The company recorded sales of RUB 861.2 million in financial year 2014 and has 118 employees. Biocom operates a modern European GMP compliant plant and was also one of the first Russian pharmaceutical manufacturing companies to receive an approved manufacturer status from the World Health Organization (WHO) in 2013.
Commenting on the acquisition, Ms. Vinita Gupta, CEO of Lupin Limited said: “We are excited about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will also enable our expansion into neighboring markets as well as other Eastern European markets in the future.”
Dr Maurice Chagnaud, President‐Europe and Head of Inhalation Strategy, commented: “Biocom is a fast growing pharmaceutical player and has recorded very positive results over the past five years. The acquisition also provides us with a strong platform to grow into the Russian market and has a lot of synergy with Lupin’s global research, technology, manufacturing and commercial expertise not to mention our global high quality product pipeline, all of which we shall leverage to grow Biocom into a market leader in the years to come.”
Mr Aleksandr Sergeyev, Biocom’s executive officer, commented: “I am delighted with Biocom’s association with Lupin. Having found, built and developed Biocom together with Mr Igor Rudinskiy for so long, I firmly believe that the future and growth of Biocom would be best handled by the management and technology expertise that Lupin brings to table. I wish Biocom and Lupin the very best in their future endeavors.”
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance